Mel Spigelman on New Regimens in Development

CPTR has helped make tremendous headway in advancing regimen development as the gold standard paradigm of TB treatment development. As such, TB Alliance has been able to conduct and complete several trials to advance the development of multiple new TB drug combinations. Dr. Spigelman offers an update on the most recent milestones and current status of the PaMZ and BPaZ regimens, as well as looks toward additional trials planned for 2015.

« »